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ABSTRACT
Transcriptional control of the genes coding for
collagen type I is regulated by a complex interaction
between a distal enhancer and a proximal promoter.
In this study, we have dissected the molecular
mechanism of this interaction by defining a specific
sequence within the enhancer that respond in
fibroblasts to transforming growth factor-b (TGF-b).
We show that TGF-b activates COL1A2 gene via
a non-canonical (Smad-independent) signalling
pathway, which requires enhancer/promoter
co-operation. This interaction involves exchange
of cJun/Jun B transcription factor occupancy of a
critical enhancer site resulting in the stabilization of
enhancer/promoter coalescence. Moreover, using
transgenesis, we show that interference in this
mechanism results in the abolition of COL1A2 fibro-
blast expression in vivo. These data are therefore
relevant to the control of collagen type I in vivo
both in embryonic development, in adult connective
tissue homeostasis, and in tissue repair and scar-
ring pathologies.
INTRODUCTION
Collagen type I is an integral structural component of the
extracellular matrix (ECM) and crucial for the formation
of connective tissues. Collagen type I is made up of two
polypeptides, COL1A1 and COL1A2, which are tran-
scribed by two separate genes. The control of these
genes requires precise regulation and organization at the
transcriptional level. Current knowledge of transcriptional
regulation of COL1A2 in vivo has been obtained primarily
from studies using promoter sequences driving transgene
expression in mice. Transgenic mice harbouring COL1A2
proximal promoter alone ( 400bp upstream of tran-
scription start site) exhibit generally low levels of activity
in late gestation embryos (E15.5) and express the trans-
gene in only a small subset of mesenchymal cells (1). The
search for other collagen type I transcriptional regulatory
sequences led to the identiﬁcation of the ‘far upstream
enhancer’ region located 21.8 to –18.8kb upstream of
the start site of transcription of the human COL1A2
gene. When this enhancer region is cloned upstream
of the proximal promoter, it increased the levels of
b-galactosidase reporter gene signiﬁcantly in almost all
mesenchymal tissues where the endogenous COL1A2 is
expressed (1). High degree of homology was found
between the human and murine enhancers (2). In addition
to the absolute requirement of the enhancer to govern
temporal and tissue-/cell-speciﬁc expression of collagen
in vivo, the presence of the enhancer has also been
shown to be essential for the re-activation of collagen
type I in adult mice during repair (3), wound healing
(4) and in pathologies such as scarring and ﬁbrosis (4–7).
Transforming growth factor-b (TGF-b) has a role in
controlling the lineage-speciﬁc expression of collagen type
I genes, as demonstrated by the high degree of temporal
and spatial correlation between activation of collagen type
I genes and the presence of TGF-b in the extracellular envi-
ronment (8). TGF-b has been shown to exert its eﬀect on
the COL1A2 gene through a TGF-b response element
(TbRE) located between nucleotides  313 and  250
upstream of the transcriptional start site in the human
COL1A2 proximal promoter (9,10). This TbRE sequence
is essential for the canonical Smad3/4-mediated TGF-b
response of this promoter and was shown to act synergis-
tically with three Sp1 sites upstream (11,12). An activator
protein-1 (AP-1) site ( 250bp), downstream of the triple
Sp1 sites, has also been shown to play a role in TGF-b
transcriptional activation of COL1A2 in vitro (13,14).
In adult tissues, TGF-b is known to be involved in the
regulation of many cellular activities, including wound
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TGF-b and the activation of its downstream targets genes
have been the focus of many investigations in biological
settings (15–19). TGF-b expression also co-localizes
with activated ﬁbroblasts responsible for most of type I
collagen deposition in ﬁbrotic diseases (20,21). In addition
to ﬁbroblasts, TGF-b can control collagen type I expres-
sion by acting on other cells, such as epithelial cells, and
promoting epithelial-to-mesenchymal transition, thus con-
tributing to the ﬁbroblast pool in kidney, lung, heart and
liver ﬁbrosis (22–26).
Since COL1A2 enhancer is critical in controlling the
level and lineage-speciﬁc expression of collagen in devel-
opment and in adult tissues, we investigated whether the
enhancer is TGF-b responsive. We report for the ﬁrst time
the presence a novel TbRE located far upstream in the
enhancer of the human COL1A2, which works indepen-
dently of the previously described TbRE in the proximal
promoter. This enhancer element activates transcription
via a non-canonical (Smad-independent) pathway invol-
ving an exchange of AP-1 family partner occupancy at a
speciﬁc site within the enhancer. We show the long-range
interaction with a critical proximal promoter site and that
mutation of this site results in the abolition of COL1A2
expression in ﬁbroblasts using reporter gene expression
in vivo.
MATERIALS AND METHODS
Cell culture
NIH3T3 mouse embryonic ﬁbroblasts were cultured in
(Gibco BRL), 10% fetal calf serum (FCS) (Gibco,
Grand Island, NY, USA). Prior to TGF-b treatment
(2.5ng/ml), the cells were serum-starved for 12h.
Primary Smad-3-null ﬁbroblasts were a kind gift from
Dr. C. Flanders (NIH, USA).
Primary human dermal ﬁbroblasts were explanted from
the skin biopsies taken with permission from healthy con-
trol subjects. Fibroblasts were maintained in Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM), 10% FCS, 100U/ml
penicillin, 100mg/ml streptomycin, and cultured in a
humidiﬁed atmosphere of 5% CO2 in air. Fibroblasts
were sub-cultured at conﬂuence and used between pas-
sages 2 and 5.
DNA constructions
The human collagen far upstream enhancer region has
been previously described by Antoniv et al. (1). Brieﬂy,
construct –378 LAC in the b-gal-Basic vector
(CLONTECH, Palo Alto, CA, USA) was derived from
the  378 COL1A2/LUC plasmid. Constructs were engi-
neered by subcloning various upstream sequences 50 of the
 378 promoter (see Supplemental Data). The HSV-thy-
midine kinase promoter (pRL-TK) (Promega) was used to
provide a heterologous promoter to replace the COL1A2
proximal promoter (see Supplemental Data).
Smaller enhancer constructs F1-pLac (–20.7kb
to  20.45kb), F2-pLac ( 20.17kb to  19.94kb) and
F3-pLac ( 18.96kb to  18.8kb) containing sequences
which include DNAse footprints (1) were made by
polymerase chain reaction (PCR) ampliﬁcation and inser-
tion into the pLAC vector.
Mutagenesis
We have followed the recommendation of Risse et al. (27)
in the mutagenesis of the AP-1 binding in the minimal
promoter and in the enhancer region (see Supplemental
Data).
Transient transfections
Transient transfection assays were performed using the
FuGENE
TM 6, according to the manufacturers’ instruc-
tions. All transfections were performed in triplicate and
repeated on more than three separate occasions. Statistical
analysis of data was performed using the Student’s t-test.
b-Galactosidase and luciferase assays
The activities of reporter genes, b-galactosidase and
luciferase, used in the transient transfection assays were
measured using the Dual-Light Chemiluminescent repor-
ter gene assay system (Tropix), according to the manufac-
turers’ instructions.
Inhibition using small interfering RNA (siRNA)
Jun B siRNA target sequences were obtained from
Dharmacon (Jun B siGenome Smartpool reagent
M-003269) and were used according to the manufacturers’
instructions. Transfection into explanted human dermal
ﬁbroblasts was achieved using the TransIT-TKO trans-
fection reagent (Mirus, MIR2150), according to the man-
ufacturers’ instructions. The siRNA was transfected at
two concentrations (5nM and 20nM). Control siRNA
was also used at the 20-nM concentration (Dharmacon,
siCONTROL, D-001210-01-20)
Sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS–PAGE) and western blot analysis
Fibroblasts were seeded (2.5 10
5cells per well) for 48h.
The cells serum were starved for 12h and treated with
or without TGF-b1 (R&D Systems Inc. UK), at 4ng/ml,
for a further 24h. The cells were lysed with Laemmli
buﬀer and analysed by SDS–PAGE, followed by West-
ern blotting. The antibodies c-jun Jun B, Jun-D
from (Santacruz), and anti-type I collagen antibody
(Southern Biotechnology Associates Inc, Birmingham,
AL, USA) were used. A chemilluminescence kit (Amer-
sham) was used to develop the western blots.
Electrophoretic mobility shift assays (EMSAs)
The nuclear extracts were used in EMSA according to the
standard protocol described in the commercially available
EMSA kit (Promega). Super-shift assays were carried out
using speciﬁc antibodies raised against phospho-c-Jun,
Jun B, Sp1, EGRF (Santa Cruz).
Chromatin immunoprecipitation (ChIP) assays
ChIP assay was performed on primary human dermal
ﬁbroblasts or on NIH3T3 ﬁbroblasts that were treated
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kit (Upstate), according to the manufacturers’ instruc-
tions. Brieﬂy, DNA–protein complexes were immunopre-
cipitated with RNA polymerase II, c-jun, Jun B, Jun D
and cAMP response element binding (CREB) antibodies
or appropriate immunoglobulin G (IgG) isotype controls
(Santa Cruz). PCR ampliﬁcations were carried out with
appropriate primers spanning the human COL1A2 pro-
moter and enhancer. These primers are human speciﬁc
(see Supplementary Data for details).
A stable mouse cell line was created, cloned from
a single NIH3T3 ﬁbroblast transfected with a construct
containing the human wild-type (WT) enhancer sequence
fused to the proximal promoter in which the AP-1 site
(at position –250bp) has been abolished (21.1/
18.8pLAC–AP-1–250) and used in ChIP assays.
Brieﬂy, the (–21.1/18.8pLAC–AP-1–250) construct was
co-transfected in NIH3T3 cells with pCDNA3. After
G418 selection, a stably transfected cell was picked and
veriﬁed by b-galactosidase assay for highest expression
and cloned.
Generation of transgenic mice
Transgenic mice were generated using standard method
as described earlier (2). E15.5 embryos were harvested
and stained for b-galactosidase as described (1,2).
RESULTS
Identification of a novel Smad-independent TGF-b
response element in the COL1A2 enhancer
Plasmid DNA constructs containing enhancer and/or
promoter fragments driving reporter gene activity were
used to determine the contribution of the human
COL1A2 far upstream enhancer compared with the prox-
imal promoter to transgene expression. These plasmids
were transfected into ﬁbroblasts, treated with or without
TGF-b, in the presence and absence of stimulatory
Smad3/4 and inhibitory Smad 7.
In NIH3T3 cell line, construct 21.1/18.8pLAC contain-
ing a 2.3-kb region of the far upstream enhancer region
fused to the proximal promoter resulted in a 6-fold
increase of reporter gene activity in the presence of
TGF-b compared with a 2-fold increase of the proximal
promoter (Figure 1A). This result was also observed in
explanted primary human dermal ﬁbroblasts, the same
construct (21.1/18.8pLAC) resulted in an  3-fold increase
of reporter gene activity in the presence of TGF-b com-
pared with a 2-fold increase of the proximal promoter
(PP) (data not shown). The subsequent transient trans-
fection studies were carried out in NIH3T3 and/or
primary human dermal ﬁbroblasts interchangeably and
with similar results.
The co-transfection of expression vectors for Smad3
(cmvSmad3) and Smad4 (cmvSmad4) with the proximal
promoter construct (–378pLAC) increased the baseline
response in both TGF-b-treated and -untreated cells,
the over-expression of the Smad3 and Smad4 did not sig-
niﬁcantly alter the response of the enhancer construct
(21.1/18.8pLAC) (Figure 1A).
Conversely, co-transfection of expression vector for
the inhibitory Smad7 (cmvSmad7) with the proximal pro-
moter construct resulted in the decrease of basal activity
as well as the complete inhibition of the TGF-b response
(Figure 1A). This is to be expected, as a Smad-dependent
TbRE has been previously identiﬁed and extensively char-
acterized within the proximal promoter (9,13).
However, what is of interest is the response of the
construct containing both the enhancer and the promoter
Figure 1. Smad-independent TGF-b activity associated with the COL1A2 far upstream enhancer region. (A) NIH 3T3 mouse ﬁbroblasts were
transiently transfected with b-galactosidase reporter gene constructs containing the COL1A2 proximal promoter alone or the COL1A2 enhancer
fused to the proximal promoter. The ﬁbroblasts were co-transfected with either a cmvSMAD7 expression vector to block Smad-dependent signalling,
or an empty cmv vector as a control, and treated with (black bars) or without (grey bars) TGF-b. Cells were also tranfected with the same reporter
gene constructs and co-transfected with or without cmvSmad3, cmvSmad4 or cmvSmad7 expression vectors. Reporter gene activity was measured.
(B) NIH3T3 ﬁbroblasts transiently transfected with b-galactosidase reporter gene constructs containing the TK proximal promoter alone or the
COL1A2 enhancer fused to the TK proximal promoter. The ﬁbroblasts were co-transfected with either a cmvSmad7 expression vector to block
Smad-dependent signalling, or an empty cmv vector as a control in treated with (black bars) or without (grey bars) TGF-b. Data for (A) and (B)
were obtained from independent experiments (n=6, mean SEM.  P<0.01 and   P<0.001 signiﬁcant increase with TGF-b treatment compared
with untreated in the same transfection group.
#Signiﬁcant reduction compared with control in the presence of Smad 7).
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of reporter gene activity with TGF-b treatment decreased
by 50%, it did not completely abolish the TGF-b response
(Figure 1A). This suggested that part of the TGF-b
response was Smad independent and associated with the
2.3kb enhancer region.
To investigate this possibility further, new DNA con-
structs were prepared in which the proximal promoter
region was replaced by a heterologous TK promoter.
The TK promoter alone has no Smad-dependent TbRE
and is not responsive to the canonical TGF-b signalling
pathway. The TK promoter was fused to the 2.3-kb
enhancer region and transfected into ﬁbroblasts, it clearly
responds to TGF-b treatment (Figure 1B). Furthermore,
co-transfection with Smad7 did not aﬀect the TGF-
b-induced activation of the reporter gene in construct
21.1/18.8–TKpLAC, supporting the hypothesis of a
Smad-independent TbRE in the far upstream enhancer
region.
Further evidence supporting a Smad-independent
mechanism is provided by transient transfections in
Smad3 knockout (KO) ﬁbroblasts completely lacking
Smad3 compared with WT ﬁbroblasts treated with and
without TGF-b (Supplementary Data, Figure 1A). The
promoter constructs 378pLAC and TKpLAC were tran-
siently transfected in these cells and, as expected, did not
respond to TGF-b. However, the constructs containing
the enhancer region attached to the minimal promoter
21.1/18.8pLAC and 21.1/18.8-TKpLAC remained TGF-
b responsive.
We also carried out a time course of TGF-b treatment
on WT and Smad3 KO ﬁbroblasts, RNA was isolated
from cells and endogenous collagen type I northern
blots were carried out using a COL1A2 speciﬁc probe.
In Smad3 KO cells, a slow incremental increase of mes-
senger RNA (mRNA) up to 40h was observed which is
more intense after TGF-b treatment (Supplementary
Data, Figure 1B). In contrast, the WT cells produced
more COL1A2 mRNA during the earlier time points
peaking after 20h and decreasing by 40h (Supplementary
Data, Figure 1B). The same pattern was observed in
the presence of TGF-b, although the mRNA levels were
overall higher. Furthermore, western analysis of Smad 3/4
in the presence of TGF-b did not change over 0–48h
(Supplementary Data, Figure 1C). However, in the same
experiment, Jun B expression appeared after 6h but no
change in the expression levels of c-jun or JunD was
observed (Supplementary Data, Figure 1D). These data
add to the body of evidence that there is, in addition to
a Smad-dependent component in the proximal promoter,
a Smad-independent TGF-b response in the enhancer
results in the transcriptional upregulation of COL1A2
gene.
Mapping the novel TbRE in the enhancer and the role
of upstream AP-1
In order to narrow down the region that contains the
putative TbRE within the 2.3-kb enhancer, we generated
smaller sub-constructs (F1, F2 and F3; Figure 2A)
that spanned the footprint regions reported by Antoniv
et al. (1). When these constructs were transfected in ﬁbro-
blasts in the presence of expression vector cmvSmad7 (to
inhibit the proximal promoter TbRE), only construct
20.17/19.94pLAC (Figure 2, F2) showed stimulation of
reporter gene activity by TGF-b (Figure 2B). This result
suggested that the 230-bp F2 sequence (Figure 2A) con-
tained a TbRE and that this activity was not dependent on
Smad signalling.
In silico surveying of putative transcription-factor-
binding sites that may be present within the F2 sequence
revealed the presence of two putative AP-1-binding sites
(Figure 2A).
In order to investigate the role of the AP-1 sites further,
we used a mutagenesis approach to generate DNA con-
structs that contained WT and AP-1 mutant sequences,
both in the proximal promoter and within the enhancer.
In the proximal promoter, a well-characterized AP-1 site
was mutated and two constructs were created. The ﬁrst
mutant construct of the proximal promoter alone, where
the AP-1 site at  250bp was abolished ( 378pLAC–dAP-
1–250), was not active in transient transfections, either in
the presence or absence of TGF-b. The same result was
observed with the second mutant, which contained the
WT enhancer fused to the mutant proximal promoter
(21.1/18.8–dAP1–250) (Figure 3). In addition, four
mutant constructs were created (21.1/18.8pLAC–dAP1–
20.34, 21.1/18.8pLAC–dAP1–20.34/20.09, 21.1/
18.8pLAC–dAP-1–20.03, 21.1/18.8pLAC–dAP-1–20.09/
20.03) in which two point mutations were introduced in
accordance with the AP-1 mutation analysis by Risse et al.
(27). Three AP-1 sites found within the enhancer were
used to generate constructs fused to a WT proximal pro-
moter. Two of these sites are located within the F2 frag-
ment (AP-1–20.03 and AP-1–20.09) (Figure 2), whilst the
third, which is 215bp upstream and outside the footprint
region (AP-1–20.34), was used as a control.
These constructs were transfected in the presence of the
cmvSmad7 expression vector and the presence/absence of
TGF-b. The results revealed that mutation of the 50AP-1
site located at –20.4kb had no eﬀect on either enhancer
activity or the TGF-b response. However, the AP-1 site
mutations within the footprinted sequence resulted in the
blocking of the TGF-b response (Figure 3).
In order to examine which AP-1 family members may
be involved in the regulation of the enhancer TbRE, we
over-expressed c-fos, c-jun, Jun B and Jun D by them-
selves and in various combinations in NIH3T3 ﬁbroblasts.
The eﬀect of the AP-1 family members was studied
in ﬁbroblasts transiently transfected with the F2 con-
struct in the presence of cmvSmad7 and the presence or
absence of TGF-b treatment (Supplementary Figure 2).
Interestingly, Jun B or Jun B/c-fos stimulated the activity
of the reporter gene,  4-fold and 3-fold, respectively, on
TGF-b treatment. JunD/c-fos heterodimers also resulted
in a 2-fold increase in reporter gene activity on TGF-b
treatment, although over-expression of JunD alone had
no eﬀect compared with control (Supplementary
Figure 2). Conversely, c-jun over-expression seemed to
have an inhibitory eﬀect potentially ‘mopping-up’ the
endogenous levels of Jun B by forming heterodimers.
Nucleic Acids Research, 2009,Vol.37, No. 16 5381Figure 2. Mapping of the TbRE within the COL1A2 enhancer. (A) Schematic representation of the far upstream enhancer region (FUE) with arrows
indicating known DNase hypersensitive sites and putative AP-1-binding sites and the proximal promoter (PP) of the human COL1A2 gene.
(B) Reporter gene constructs containing regions of the COL1A2 far upstream enhancer which have been shown in ﬁbroblasts to contain ‘footprints’
(F1, F2 and F3) of open chromatin were transfected in human primary dermal ﬁbroblasts, co-transfected with cmvSmad7 expression vector to inhibit
Smad signalling and treated with (black bars) or without (grey bars) TGF-b.( n=6, mean SEM   indicates signiﬁcant increase P<0.001 with
TGF-b treatment compared with untreated in the same transfection group).
Figure 3. Mutation of key AP-1 sites in COL1A2 results in inhibition of transcriptional activity. Site-directed mutagenesis (x) was carried out on
AP-1 consensus sites located either within the proximal promoter or the far upstream enhancer region. The mutated sequences transiently transfected
with b-galactosidase reporter gene constructs containing either the enhancer F2 or the proximal promoter alone. Co-transfection with cmvSmad7
expression vector was used to block Smad-dependent signalling from proximal promoter in treated with (black bars) or without (grey bars) TGF-b
(n=6, mean SEM.  P<0.01 or   P<0.001 signiﬁcant decrease with TGF-b treatment of mutated enhancer sequences compared with
intact enhancer.
#Indicates signiﬁcant decrease (P<0.001) in mutated proximal promoter in the presence of an enhancer compared with control,
21.1/18.8pLAC).
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blasts and similar results were obtained (data not shown).
Having identiﬁed two putative AP-1 regulatory sites
within the F2 fragment, their functional signiﬁcance, in
terms of TGF-b treatment, was further investigated
using EMSA. Three overlapping double-stranded DNA
(dsDNA) oligonucleotides (GS-30bp, GS-50bp and GS-
24bp) spanning the footprint region within 20.17/20.94
pLAC were synthesized and radiolabelled for the EMSA
probes used with nuclear extracts from NIH3T3 cells trea-
ted with and without TGF-b (data not shown). Although
DNA/protein complexes were observed with all three
probes, the only ones that altered with TGF-b treatment
were with the GS-24bp probe (Figure 4). The GS-24-bp
probe which contained the putative AP-1 site (–20.03kb),
used in binding reactions with untreated nuclear extracts
revealed three DNA/protein complexes (C1, C2 and C3)
(Figure 4A). In the presence of TGF-b-treated nuclear
extracts, DNA/protein complex C1 was lost, C2 dimin-
ished, C3 increased and, a new complex, C4 appeared
(Figure 4A and B). These complexes were speciﬁc as
shown by the addition of the unlabelled competitor oligo-
nucleotide. Furthermore, by mutating the AP-1 site within
the GS-24bp probe, all DNA/protein complexes were lost
apart from C2 which diminished signiﬁcantly (Figure 4A).
In addition, super-shift reactions using anti-c-Jun block-
ing antibody, complex C2 diminishes indicating that the
shift contains c-jun (Figure 4B). Complexes C3 and C4
that are present only in the TGF-b-treated samples were
diminished or abolished when anti-Jun B antibodies were
used in the binding reactions, suggesting that these com-
plexes contain Jun B, while complex C1 remains unaltered
(Figure 4B). Isotype control antibodies [Sp1, epidermal
growth factor receptor (EGFR)] were also used but had
no aﬀect on the binding in either the absence or presence of
TGF-b (data not shown). A time course of up to 30h with
TGF-b shows a diminishing c-jun and a shift appearing
for Jun B (Figure 4C). These data suggest that there is an
alteration in the DNA/protein complex (s) that can form at
position –20.03kb after TGF-b treatment–from one that
contains c-jun to one that contains Jun B.
The role of Jun B on COL1A2 expression
Thus far, the data obtained suggested that AP-1 site
at position –20.03kb is involved in the transcriptional
activation of the gene after TGF-b treatment and that
Jun B is part of the DNA/protein complex that brings
about this activation. Jun B is not highly expressed by
untreated human skin ﬁbroblast unlike c-jun and JunD,
which are constitutively expressed. Furthermore, upon
TGF-b activation, Jun B is upregulated and continues to
be expressed for at least 48h after treatment (Supplemen-
tary Figure 1D). Further experiments were carried out
using siRNA for Jun B showing that transgene activity
was also diminished in a dose–response manner, whilst
control siRNA had no eﬀect (Supplementary
Figure 3A). The inhibition was evident in both TGF-b-
treated and untreated cells, although the eﬀect was greater
in TGF-b-treated cells. Thus, depletion of Jun B resulted
in a decrease of the activity of the F2 enhancer region in a
dose–response manner in both TGF-b-treated and
untreated cells. Interestingly, inhibition of Jun B not
only blocked the TGF-b response but also the basal
levels of enhancer activity, suggesting that Jun B is
Figure 4. JunB displaces c-jun on the COL12 enhancer after TGF-b activation (A) EMSAs were carried out using a 24-bp labelled oligonucleotide
probe spanning the AP-1 sites within the F2 COL1A2 enhancer region. Nuclear extracts (NE) from NIH3T3 ﬁbroblasts treated or untreated
with TGF-b were used in EMSA. Cold competitor oligonucleotides were also used to verify speciﬁcity of the DNA/protein complexes using
the wild type probe. A mutant probe, in which AP-1 binding was abolished, was also used in EMSAs. (B) Super-shift assays were carried out
using speciﬁc antibodies for either c-jun or Jun B in which NE were incubated with the antibodies prior to the addition of the probe. DNA/protein
complexes (C1 to C4) were identiﬁed. (C) Time course of treatment with TGF-b showing Jun B binding with diminishing c-jun.
Nucleic Acids Research, 2009,Vol.37, No. 16 5383involved in enhancer function. Similar results were also
obtained with TK heterologous promoter (Supplementary
Figure 3B).
We hypothesized that upon TGF-b activation, upregu-
lation of Jun B will also lead to upregulation of collagen
type I protein. Therefore, inhibition of Jun B expression
using siRNA should result in inhibition of collagen type I
protein. Indeed, speciﬁc inhibition of Jun B in a dose–
response manner was achieved using siRNA on human
dermal ﬁbroblasts (Figure 5A). This siRNA treatment
did not have an eﬀect on the level of either c-jun or Jun
D (Figure 5A, lower panel). Similarly, siRNA for c-Jun
did reduce the collagen type I protein levels but not in the
presence of TGF-b (Figure 5B), while siRNA for Jun D
had very little eﬀect on the collagen type I level in the
presence of TGF-b (Figure 5C)
The role of Jun B on the transcriptional activity of
the COL1A2 enhancer was further investigated in vivo
in human dermal ﬁbroblasts using ChIP assays
(Figure 6A). The explanted ﬁbroblasts were treated with
and without TGF-b followed by ﬁxation and fragmenta-
tion of the chromatin into fragments of around 500bp.
Immunoprecipitation was then carried out using RNA
polymerase II antibody followed by puriﬁcation of the
DNA from the immunoprecipitated chromatin complexes
and ampliﬁcation using primers speciﬁc to the proximal
promoter and the F2 fragment. RNA polymerase II is a
multi-subunit DNA-binding enzyme responsible for tran-
scriptional initiation by recruiting and co-ordinating the
various components of the transcriptional complex, which
interact with the gene promoter. As expected, RNA poly-
merase II co-precipitated with the proximal promoter
DNA (PP) which contains the transcriptional start site
in the cells which were both treated and untreated
with TGF-b (Figure 6A). The F2 enhancer fragment
also co-precipitated with RNA polymerase II immuno-
precipitation. As RNA polymerase II does not bind
directly on the enhancer, this result suggests that the F2
fragment of the enhancer is interacting directly with the
proximal promoter in both TGF-b-treated and -untreated
cells since c-jun precipitated with both the proximal pro-
moter DNA (PP) and the F2 fragment (Figure 6A).
However, there was a signiﬁcant decrease of the F2 PCR
product with TGF-b treatment, suggesting that less F2/
c-jun complexes were available for ampliﬁcation under
these conditions. PP/c-jun complexes increased with
TGF-b treatment.
Jun B did not precipitate with the F2 fragment and the
level of PP PCR product was relatively low in the
untreated cells; however, with TGF-b treatment both
F2/Jun B and PP/Jun B complexes formed. These results
are in agreement with the data that Jun B is not constitu-
tively expressed in untreated skin ﬁbroblasts, although it
is increased with TGF-b treatment. The ChIP data clearly
show that the TGF-b response of the enhancer is mediated
through a decrease in F2/c-jun complexes and increase
of F2/Jun B complexes interacting with the proximal
promoter.
We have also used mouse cells cloned from a single
NIH3T3 ﬁbroblast stably transfected with a construct
containing the human WT enhancer sequence fused to
the proximal promoter in which the AP-1 site (at position
–250bp) has been abolished (21.1/18.8pLAC–dAP-1–250)
in ChIP assays in order to investigate further if this site is
involved in either the enhancer TGF-b response or in the
recruitment of the enhancer to the promoter during this
response. For comparison we have a stably transfected
line of NIH3T3 ﬁbroblasts containing the WT human
enhancer and promoter sequences (21.1/18.8pLAC).
After TGF-b treatment, ChIP assays were performed
and the puriﬁed DNA was ampliﬁed using primers that
can only PCR the human sequence, therefore allowing for
the detection of the transfected DNA rather than the
endogenous mouse DNA. ChIP assays were carried out
using antibodies against RNA polymerase II, c-jun, Jun B,
JunD and CREB (Figure 6B). In the WT cells, the results
conﬁrmed the data obtained in human dermal ﬁbroblasts
as previously shown in Figure 6A, that RNA polymerase
II co-precipitated with the PP in both the absence and
presence of TGF-b stimulation and co-precipitated the
F2 fragment indicating that PP and enhancer are interact-
ing. In WT cells c-jun occupies the PP and F2 enhancer
region in the absence of TGF-b stimulation, whereas,
Figure 5. Eﬀect of siRNA knockdown of AP-1 family on Collagen
type I. Human primary dermal ﬁbroblasts were treated with Jun B
siRNA (10nM and 25nM) or a scrambled siRNA (25nM) in the pres-
ence or absence of TGF-b. SDS–PAGE and western blot analysis of
the protein levels of Jun B or Collagen type I (Col I) were assessed with
speciﬁc antibodies (A). c-jun and Jun D levels do not change (A, lower
panel) as with GAPDH used as a loading control. The ﬁbroblasts were
also treated with siRNA for c-jun (B) and Jun D (C).
5384 Nucleic Acids Research, 2009, Vol. 37,No. 16upon TGF-ß treatment, Jun B binds more strongly to
both the PP and F2 regions whilst the levels of F2/c-jun
complexes decrease signiﬁcantly (Figure 6B, left versus
right panel). In addition, TGF-b stimulation also results
in increased binding of Jun D and CREB on both the PP
and F2 DNA (Figure 6B). However, in the stable cell line,
where the AP1 site in the proximal promoter had been
mutated (21.1/18.8pLAC–dAP-1–250), there appears to
be little or no binding either of the AP-1 family members
on the PP DNA or on the F2 enhancer region in absence
of TGF-b, whereas TGF-b stimulation only slightly
increases the level of binding (Figure 6C). Interestingly,
the abolition of that AP-1 site in the PP results in the
inability of RNA polymerase II to remain bound on the
promoter, suggesting that AP-1 binding to this site has an
essential role in the normal function of the transcriptional
machinery (Figure 6C). Not surprisingly, F2/RNA poly-
merase II complexes are not observed indicating that the
enhancer requires both an AP-1 site and RNA polymerase
II containing complex before it can interact with the
proximal promoter (Figure 6C).
To test the signiﬁcance of this ﬁnding, transgenic
mice were generated harbouring the intact enhancer and
an AP-1 mutated 21.1/18.8pLAC–dAP-1–250 construct
(Figure 7). The results showed a mutation in proximal
promoter AP-1 leads to a complete lack of expression
of the transgene in all the transgenic embryos obtained.
The absence of even the minimal levels of expression
observed in transgenic mice harbouring the proximal
promoter alone, suggests that the AP-1 in the proximal
promoter is necessary for the in vivo activity of the
upstream enhancer as well as the proximal promoter of
the COL1A2 gene. A surprising result was also obtained
when a mutation of the 21.1/18.8pLAC–dAP-1–20.03 con-
struct was analysed in embryos showing a signiﬁcant
attenuation of the ﬁbroblast transgene expression in all
ﬁbroblasts, including skin (Figure 7, lower right panel).
Analysis of all embryos showed  30% of pups are trans-
genics and 40% of those expressed the LacZ transgene.
In each of the expressing lines, three embryos expressed
the transgene in similar spacio-temporal fashion, indicat-
ing that the integration site does not aﬀect the expression
in signiﬁcant manner.
DISCUSSION
TGF-b has a pleiotropic eﬀect in vivo, exerted through
a range of pathways, which involve diﬀerent signal mole-
cules depending on the target cell. Each of these pathways
is initiated by the binding of transcription factors to target
Figure 6. In vivo interactions of the COL1A2 enhancer and proximal promoter. (A) Primary human dermal ﬁbroblasts treated or untreated with
TGF-b were used in ChIP assays. PCR reactions were carried out using speciﬁc primers for the F2 region of the COL1A2 enhancer or the proximal
promoter (PP). Ten percent of input was used as positive control. Antibodies for RNA polymerase II (RNA PolII), c-jun and JunB were used to
immunoprecipitate the protein/DNA complexes. Appropriate isotype-speciﬁc controls were also performed. (B) ChIP assays were also carried out
on NIH3T3 cell lines stably transfected with constructs containing either the wild-type human enhancer sequence fused to the proximal promoter
(21.1/18.8pLAC). In (C), the wild-type human enhancer sequence fused to the proximal promoter in which the AP1 site at position –250 has been
mutated (21.1/18.8pLAC–d–AP-1–250). Antibodies for RNA PolII, c-jun, JunB, JunD and CREB were used to immunoprecipitate the protein/DNA
complexes. Appropriate negative IgG controls were also performed.
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factors involved in TGF-b signalling, although others
have been shown to bind to native DNA and associate
with Smad proteins to induce activation/repression of
target gene promoters (28,29). Some of the activating
factors include Sp1, AP-1, Runx, Fox and bZip, to
name but a few (30–32).
The central question in this study is: How does TGF-b
activate the synthesis of collagen type I, especially in the
light of the relatively recent discovery of the far upstream
enhancer within the COL1A2 gene which has been shown
to play an important role in the full expression of collagen
type I in vivo during development (8) in adult tissue repair
(3) and in ﬁbrotic mouse models (5,33).
At the molecular level, a series of experiments from
several laboratories has shown that the COL1A2 pro-
moter harbouring a CAGACA consensus sequence in
the proximal promoter between –378 and +52bp, binds
Smad3/Smad4 complexes, which mediate the TGF-b-
induced COL1A2 transcription in human skin ﬁbroblasts.
Furthermore, a cytokine response element (TbRE –313bp
to –250bp) was coined to include a C/EBP site, three Sp1,
CAGA and AP-1-binding sites which contribute to
collagen gene regulation (9).
Within the TbRE, a cis-acting element containing a
CAGA box was identiﬁed (between nucleotides  269
and  261) a sequence motif which binds Smad3/
Smad4 complexes and is located directly 30 of three
Sp-1 transcription-factor-binding sites and 50 of an
AP-1-binding site. It was found that Smad 3/4 binding
was not suﬃcient to drive TGF-b activation of the
COL1A2 gene. There is still some controversy as to
the extent by which AP-1 versus Sp1 contribute to the
TGF-b response of basal COL1A2. The three Sp1,
between nucleotides –304 to  273 and TGF-b, were
shown to be critical for COL1A2 transcription by
increasing the aﬃnity of an Sp-l-containing protein com-
plex for its cognate DNA-binding site and complexing
with Smad proteins (9–11). Chung et al. (13) showed
that AP-1-binding site located 30 of the TbREs plays a
signiﬁcant role in the basal activity of the promoter and
TGF-b induction (14). Since these original ﬁndings, the
discovery of the upstream enhancer and its role in coor-
dinating the full response of COL1A2 gene in vivo has
Figure 7. Mutation of AP-1 sites in proximal promoter and enhancer aﬀect COL1A2 expression in transgenic mice. Transgenic mice were
generated harbouring either the (21.1/18.8pLAC) shows expression in fascia of skin (left panel) and all collagen type I producing cells as previously
shown. The 21.1/18.8pLAC–d–AP-1–250 construct shows no expression in embryos and as illustrated in cross-section of skin (middle panel).
However, 21.1/18.8pLAC–d–AP-1–20.03 showed attenuated lacZ activity in ﬁbroblasts of most organs and very little in skin sagital section
(right panel).
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this study.
The experiments outlined in this study show clearly
that, in human adult ﬁbroblasts and NIH3T3 cells,
TGF-b engages the upstream enhancer not through
Smad-binding sites but via complexes containing AP-1
family members. We veriﬁed this activity by using a het-
erologous minimal TK promoter, which has no TGF-b
response element, by over-expression of Smad 7, an inhib-
itor of canonical TGF-b pathway, and in Smad3-null
cells. We identiﬁed the sequence in the enhancer that is
responsible for increased activity of COL1A2 after TGF-b
treatment and showed it to be located at around –20kb
away from the transcription start site, where two AP-1
binding sites were shown to be potentially involved. It is
notable that this enhancer sequence spans a previously
identiﬁed footprint (F2) in lung ﬁbroblasts. Moreover,
this region falls amongst two DNAse 1 hypersensitive
sites (5 and 4) in chromatin described in our earlier pub-
lication and indicating the open transcriptional status of
this region (1).
Expression vectors for Jun B and Jun D were found to
signiﬁcantly increase transgene levels of this enhancer
sequence in the presence of TGF-b, while EMSA
showed binding of Jun B to the identiﬁed elements and
its knockdown signiﬁcantly abolishes the eﬀect of TGF-b
on enhancer and reduces basal level of transcription.
However, it is not fully understood why inhibition of
Jun B in untreated cells reduces signiﬁcantly the activity
of the enhancer (Supplementary Figure 3) when expres-
sion levels of Jun B in untreated cells are low (Figure 5A).
Clearly, the data suggest that there is a greater role for
Jun B in the normal function of the enhancer.
AP-1 complexes form dimers of gene products of
the Fos and Jun families, which have closely related
recognition sites but diﬀerent transcriptional activities
and DNA-binding aﬃnities. Moreover, modulation of
AP-1/Jun expression by TGF-b is a cell-type-speciﬁc phe-
nomenon, as TGF-b activates c-jun expression only in
epithelial cells, whereas it induces Jun B in mesenchymal
cells (34).
The ChIP data in this study clearly show a switch from
c-jun to Jun B in the F2 sequence when TGF-b is added,
while Jun B is always binding in the proximal promoter
(Figure 6A) indicating perhaps that Jun B does relieve the
repression of the c-jun exerted on COL1A2, as shown by
Chung et al. The data from the ChIP assay experiments on
ﬁbroblast stable cell lines expressing the AP-1 mutant in
the proximal promoter in the presence of the whole 2.3-kb
enhancer are intriguing. The absence of the
RNA polymerase II PCR product in those cells compared
with WT construct indicate that the ability of the
enhancer to engage with the proximal promoter is depen-
dent on an AP-1 family member binding on the –250-bp
site within the proximal promoter. The stability of
this complex whether TGF-b induced or not, requires
this interaction and appears to be mediated primarily by
Jun B.
Based on the ChIP and in vivo evidence in this study,
we propose that an AP-1 complex binding at –250bp and
enhancer (F2) plays an essential role in mediating the
recruitment of the enhancer to the proximal promoter
and stabilization of this interaction allows transcription
of COL1A2
This suggestion is also based on other in vivo evi-
dence of mutated key transcription-factor-binding sites
(CBF, Sp1/Sp3) in the proximal promoter to assess
the co-ordinate expression of enhancer/promoter dur-
ing development (35). The results showed that tissue spe-
ciﬁcity and intensity of expression is altered suggesting
that cooperation between the enhancer and basal pro-
moter is required. Given that the mutation of AP-1 site
in the proximal promoter in the presence of the enhancer
diminishes the transcriptional read out of the COL1A2
gene in transient expression abolishes the binding of the
RNA polymerase II in ChIP assays and shows no expres-
sion in 40 transgenic embryos, when normally one would
expect 40% expression, can only suggest that the func-
tional AP-1 site in proximal promoter is required for
the formation of an enhancesome, which recruits the
upstream enhancer sequence to coordinate the expression
of the collagen type I gene. TGF-b may be involved in this
recruitment since there is a correlation of type I collagen
gene expression during mouse embryogenesis with extra-
cellular localization of TGF-b. What is notable is the
expression in embryos which had two-point substitution
in the AP-1 enhancer site. Almost complete attenuation of
ﬁbroblast expression not only in the skin but also in many
internal organs compared to the enhancer suggesting
perhaps that the AP-1 interaction along with other
motifs may be critical for ﬁbroblast-speciﬁc expression.
Furthermore, we propose that the increase in transcrip-
tional synergy when the enhancer is engaged, may be a
reﬂection of an intrinsic DNA bend mediated by ﬂanking
sequences outside the core AP-1 recognition element
site, which can strongly increase transcriptional activity
as previously shown (36,37). Knowing the location of
transcriptionally active DNAse I hypersensitive sites
along the COL1A2 promoter and given that repressors
have been deﬁned at –2.0kb and +0.7kb (1,38), we
would speculate that the interaction between enhancer
and proximal promoter in this gene favours DNA looping
rather than scanning as a mode of enhancer–promoter
cross-talk to activate the COL1A2 gene. In summary,
this study provides a paradigm for cytokine modulation
of chromatin re-arrangement and provides yet another
example of transcription-factor-dependent dynamic recon-
ﬁguration of long-range enhancer–promoter interactions.
We propose a potential mechanism by which enhanced
levels of COL1A2 expression are achieved by TGF-b
induction of Jun-B. A re-organization of the chromatin
structure of COL1A2 is followed by a displacement
of c-jun by Jun B on a speciﬁc AP-1-binding site
( 20.03kb) within the far upstream enhancer region,
resulting in the stabilization of enhancer/promoter
interaction.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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